Seeing acceleration in “markets that matter most.” Expects full year MedTech tariff impact about $500M. Does not see any material impact on MedTech performance from One Big Beautiful Bill or loss of ACA subsidies. Expects to be a “formidable player” in surgical robotics. Expects to appeal recent talc decision.
Claim 50% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on JNJ:
- Johnson & Johnson says entering 2026 with ‘powerful momentum’
- Morning Movers: Netflix shares slide despite earnings beat
- Johnson & Johnson says ‘leading, expanding position’ in each of its businesses
- Options Volatility and Implied Earnings Moves Today, January 21, 2026
- JNJ Earnings: Johnson & Johnson Stock Falls Despite Q4 Revenue Beat